Core Viewpoint - The company expects a net profit of 86.61 million yuan for the first three quarters of 2025, representing a year-on-year increase of 48.99% [1] Financial Performance - The company has effectively implemented budget optimization and cost control measures, resulting in a year-on-year decrease in period expenses, which supports the stable development of its overall business [1] - The new materials and machinery business segments have benefited from the successful commercialization of certain R&D projects, leading to improvements in both revenue and gross profit compared to the previous year [1] - The estimated impact of non-recurring gains and losses on net profit for the reporting period is approximately 17.48 million yuan [1]
金石亚药:预计前三季度净利润同比增长48.99%